PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics News - 7th May 2025
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes News - 10th September 2024
PhoreMost Achieves Second Milestone in Target Discovery Alliance with Boehringer Ingelheim News - 3rd June 2024